Iterum Therapeutics Total Assets 2011-2026 | ITRM

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Iterum Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
44.6 M	26.3 M	66.8 M	91.5 M	32.8 M	25.8 M	97.9 M	46.8 M	26.9 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
97.9 M	25.8 M	51 M

Quarterly Total Assets Iterum Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
32.5 M	34 M	33 M	15.9 M	14.2 M	19.6 M	39.7 M	51 M	58.1 M	66.8 M	71.6 M	76.7 M	84.1 M	91.5 M	98.4 M	106 M	115 M	32.8 M	32.8 M	32.8 M	32.8 M	25.8 M	25.8 M	25.8 M	25.8 M	97.9 M	97.9 M	97.9 M	97.9 M	46.8 M	46.8 M	46.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
115 M	14.2 M	55.4 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Aquestive Therapeutics AQST	160 M	$ 4.16	1.46 %	$ 445 M	USA
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	1.08 B	$ 9.77	1.82 %	$ 632 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Burford Capital Limited BUR	3.11 B	$ 5.15	4.46 %	$ 793 M	Britain
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
BioNTech SE BNTX	22 B	$ 98.14	-5.13 %	$ 27.2 B	Germany
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	1.19 B	$ 22.15	-1.36 %	$ 3.67 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	92.2 M	-	-	$ 269 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
Cerus Corporation CERS	222 M	$ 2.79	37.44 %	$ 532 M	USA
Atreca BCEL	155 M	-	-11.76 %	$ 5.79 M	USA
Berkeley Lights BLI	226 M	-	-7.31 %	$ 87 M	USA
Calithera Biosciences CALA	64.8 M	-	-10.95 %	$ 876 K	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
CymaBay Therapeutics CBAY	435 M	-	-	$ 3.45 B	USA
ChemoCentryx CCXI	426 M	-	-	$ 3.74 B	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Caladrius Biosciences CLBS	35 M	-	-16.75 %	$ 25.8 M	USA
Checkmate Pharmaceuticals CMPI	78.8 M	-	-	$ 231 M	USA
Cardiff Oncology CRDF	61.9 M	$ 1.72	-0.87 %	$ 115 M	USA
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
Brainstorm Cell Therapeutics BCLI	1.02 M	-	-2.5 %	$ 5.88 M	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Deciphera Pharmaceuticals DCPH	474 M	-	-	$ 2.18 B	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Innate Pharma S.A. IPHA	62.7 M	$ 1.49	3.12 %	$ 235 M	France
Dynavax Technologies Corporation DVAX	986 M	-	-	$ 2.02 B	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 2.93	-8.15 %	$ 4.82 M	Israel
Eiger BioPharmaceuticals EIGR	38.8 M	-	-9.21 %	$ 2.55 M	USA
Editas Medicine EDIT	187 M	$ 2.9	-3.48 %	$ 257 M	USA
Eloxx Pharmaceuticals ELOX	21.1 M	-	-5.68 %	$ 8.28 M	USA
Edesa Biotech EDSA	3.81 M	$ 17.81	-2.57 %	$ 56.9 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA